Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
Provided By GlobeNewswire
Last update: Jun 25, 2024
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –
– Skin biopsies from subjects treated with AK006 show high receptor occupancy –
– AK006 was well-tolerated with a favorable safety profile –
